Autopsy report · NCT01851174

Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

“PI Leaving Site”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 15 participants enrolled.
• Results were posted on the registry 2 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Western Regional Medical Center

Sponsor type

University, hospital or other

Conditions

Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer

Interventions

Gemcitabine; nab-Paclitaxel

Participants

15

Sites

1

Countries

United States

Trials that died the same way

• Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics
  “PI left site” (89% match in meaning)
• Analysis of Cardiac Biomarker Racial Discrepancies
  “PI no longer with the site” (78% match in meaning)
• Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure
  “Departure of PI” (72% match in meaning)
• SCD Fit Homebase Program
  “PI leaving institution” (72% match in meaning)
• Brain Autoregulation Research Study
  “PI departure” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.